Abstract:Background YTH domain family (YTHDF) 2 acts as a “reader” protein for RNA methylation, which is important in tumor regulation. However, the effect of YTHDF2 in liver hepatocellular carcinoma (LIHC) has yet to be elucidated. Methods We explored the role of YTHDF2 in LIHC based on publicly available datasets [The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Gene Expression Omnibus (GEO)]. A bioinformatics approach was employed to analyze YTHDF2 . Logistic regression analyses were applied to analyze the correlation between YTHDF2 expression and clinical characteristics. To evaluate the effect of YTHDF2 on the prognosis of LIHC patients, we used Kaplan–Meier (K–M) curves. Gene set enrichment analysis (GSEA) was undertaken using TCGA dataset. Univariate and multivariate Cox analyses were used to ascertain the correlations between YTHDF2 expression and clinicopathologic characteristics with survival. Genes co-expressed with YTHDF2 were identified and detected using publicly available datasets [LinkedOmics, University of California, Santa Cruz (UCSC), Gene Expression Profiling Interactive Analysis (GEPIA), and GEO]. Correlations between YTHDF2 and infiltration of immune cells were investigated by Tumor Immune Estimation Resource (TIMER) and GEPIA. Results mRNA and protein expression of YTHDF2 was significantly higher in LIHC tissues than in non-cancerous tissues. High YTHDF2 expression in LIHC was associated with poor prognostic clinical factors (high stage, grade, and T classification). K–M analyses indicated that high YTHDF2 expression was correlated with an unfavorable prognosis. Univariate and multivariate Cox analyses revealed that YTHDF2 was an independent factor for a poor prognosis in LIHC patients. GSEA revealed that the high-expression phenotype of YTHDF2 was consistent with the molecular pathways implicated in LIHC carcinogenesis. Analyses of receiver operating characteristic curves showed that YTHDF2 might have a diagnostic value in LIHC patients. YTHDF2 expression was associated positively with SF3A3 expression, which implied that they may cooperate in LIHC progression. YTHDF2 expression was associated with infiltration of immune cells and their marker genes. YTHDF2 had the potential to regulate polarization of tumor-associated macrophages, induce T-cell exhaustion, and activate T-regulatory cells. Conclusion YTHDF2 may be a promising biomarker for the diagnosis and prognosis of LIHC and may provide new directions and strategies for LIHC treatment.

N6-methyladenosine binding protein YTHDF2 predicts better prognosis in patients with gastric cancer

The Methylation Modification of M6a Regulators Contributes to the Prognosis of Head and Neck Squamous Cell Carcinoma

M6a Reader YTHDF3 is Associated with Clinical Prognosis, Related RNA Signatures and Immunosuppression in Gastric Cancer.

M(6)A Rna Methylation Regulator Ythdf1 Correlated With Immune Microenvironment Predicts Clinical Outcomes And Therapeutic Efficacy In Breast Cancer

m6A RNA Methylation Regulator YTHDF1 Correlated With Immune Microenvironment Predicts Clinical Outcomes and Therapeutic Efficacy in Breast Cancer

N6-methyladenosine Related Gene Expression Signatures for Predicting the Overall Survival and Immune Responses of Patients with Colorectal Cancer

The N6-Methyladenosine (m6a) Methylation Gene YTHDF1 Reveals a Potential Diagnostic Role for Gastric Cancer

m 6 A reader YTHDF3 is associated with clinical prognosis, related RNA signatures and immunosuppression in gastric cancer

YTHDF2 exerts tumor-suppressor roles in gastric cancer via up-regulating PPP2CA independently of m 6 A modification

Comprehensive Analysis of M6a Reader YTHDF2 Prognosis, Immune Infiltration, and Related Regulatory Networks in Hepatocellular Carcinoma

The m<SUP>6</SUP>A Reader YTHDF1 Facilitates the Tumorigenesis and Metastasis of Gastric Cancer via USP14 Translation in an m<SUP>6</SUP>A-Dependent Manner

N6-Methyladenosine RNA-Binding Protein YTHDF1 in Gastrointestinal Cancers: Function, Molecular Mechanism and Clinical Implication

Prognostic Value of YTHDF2 in Clear Cell Renal Cell Carcinoma

YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of FZD7

Systematic Analyses of the Role of the Reader Protein of N6-Methyladenosine RNA Methylation, YTH Domain Family 2, in Liver Hepatocellular Carcinoma

The N6-methyladenosine Reader Protein YTHDC2 Promotes Gastric Cancer Progression Via Enhancing YAP Mrna Translation

Prognostic analysis of patients with gastric cancer based on N6-methyladenosine modification patterns and tumor microenvironment characterization

Integrated Clinical and Prognostic Analysis of the M6a RNA Methylation Regulator YTHDF3 in Pan-Cancer and Its Correlation with Cancer Cell Proliferation

Downregulation of M6a Reader YTHDC2 Promotes Tumor Progression and Predicts Poor Prognosis in Non‐small Cell Lung Cancer

Up-Regulation of YTHDF1 and YTHDF3 is Related to the Prognosis of Oral Squamous Cell Carcinoma

Expression Status and Prognostic Roles of M6a-Related Genes in Multiple Myeloma: YTHDF2 As the Independent Prognostic Factor